1-6 of 6
Petra Krhovska
Close
Sort by
Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Capkova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Martin Mistrik, Jaroslav Bacovsky, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2021) 138 (Supplement 1): 2716.
https://doi.org/10.1182/blood-2021-148836
Published: 2021
Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Jiri Minarik, MD PhD, Tomas Pika, MD PhD, Jakub Radocha, Alexandra Jungova, Jan Straub, MD, Tomas Jelinek, MD, Ludek Pour, MD, Petr Pavlicek, MD, Martin Mistrik, MD PhD, Lucie Brožová, MSc, Petra Krhovska, Katerina Machalkova, Pavel Jindra, MD PhD, Ivan Spicka, MD PhD Prof, Hana Plonkova, MD, Martin Stork, MD, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, MD, Lukáš Stejskal, MD, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, MD, Vladimir Maisnar, MD PhD MBA, Roman Hajek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3139.
https://doi.org/10.1182/blood-2019-128865
Published: 2019
Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Jiri Minarik, MD PhD, Petra Krhovska, Tomas Jelinek, Alexandra Jungova, Martin Mistrik, MD PhD, Tomas Pika, MD PhD, Evzen Gregora, MD, Vladimir Maisnar, MD, Jan Straub, MD, Ludek Pour, MD, Lucie Brozova, MSc, Jaroslav Bacovsky, Hana Plonkova, Pavel Jindra, MD PhD, Petr Pavlicek, MD, Jakub Radocha, MD, Ivan Spicka, MDPhDProf, Martin Stork, MD, Vlastimil Scudla, Prof, MD CSc, Roman Hajek
Journal: Blood
Blood (2018) 132 (Supplement 1): 1959.
https://doi.org/10.1182/blood-2018-99-112046
Published: 2018
Journal Articles

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Jiri Minarik, MD PhD, Edgar Faber, MD, Ludek Raida, MD PhD, Tomas Szotkowski, MD, Jaroslav Bacovsky, Tomas Pika, MD PhD, Ivana Skoumalova, MD PhD, Petra Krhovska, Jana Zapletalova, Mgr., PhD, Tomas Papajik, MD prof, Vlastimil Scudla, Prof, MD CSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 5749.
https://doi.org/10.1182/blood-2018-99-112115
Published: 2018
Journal Articles

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Jiri Minarik, MD PhD, Ludek Pour, MD PhD, Vladimir Maisnar, Prof, MD PhD, Ivan Spicka, MDPhD, Alexandra Jungova, MD, Hana Plonkova, Lucie Brozova, MSc, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Sabina Sevcikova, RNDr, PhD, Jakub Radocha, MD PhD, Vlastimil Scudla, Prof, MD CSc, Roman Hájek, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5414.
https://doi.org/10.1182/blood.V130.Suppl_1.5414.5414
Published: 2017
Journal Articles

Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors

Jiri Minarik, MD PhD, Zuzana Hermanova, Jan Hrbek, Pavla Petrova, Patrik Flodr, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Miroslav Herman, Vlastimil Scudla
Journal: Blood
Blood (2016) 128 (22): 5603.
https://doi.org/10.1182/blood.V128.22.5603.5603
Published: 2016